Aptevo Therapeutics entered into a Grant Award Agreement with the Andy Hill CARE Fund to support IND-enabling studies for APVO451, its trispecific antibody for solid tumors. The $1,499,951 award is reimbursable against eligible costs and requires Aptevo to provide at least matching non-state contributions. The project period runs through June 2028 and payments are tied to milestones, reporting, and compliance obligations. Aptevo retains project IP, subject to acknowledgments and commitments related to commercialization and public benefit.
Agreement details:
- Agreement type: Grant Award Agreement for reimbursable research funding
- Counterparty: Andy Hill CARE Fund
- Signed / Effective: Jun 29 2026 / same
- Duration / Termination: Through June 2028
- Reason: Fund IND-enabling studies for APVO451
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.